Inflamed, itchy and sometimes painful skin lesions on the hands can significantly impair quality of life. If chronic hand eczema proves to be refractory to topical treatment, systemic therapy is called for. In addition to alitretinoin, the topical JAK inhibitor delgocitinib is now available in Switzerland as a further systemic therapy option and several representatives of JAK-i and biologics are being researched.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Pain and autism
Hurdles to pain treatment for autistic patients
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal